Related Experiment Video
Updated: Dec 22, 2025
Quantification of Antibody-dependent Enhancement of the Zika Virus in Primary Human Cells
Published on: January 18, 2019
Analysis of Serum Anti-Zika Virus Antibodies by Focus Reduction Neutralization Test
Jessica L Smith1,2, Alec J Hirsch3,4
1The Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA. smijessi@ohsu.edu.
Zika virus (ZIKV) is a newly emerged mosquito-borne flavivirus that has been associated with birth defects of babies born to ZIKV-infected mothers. Neutralization activity of serum derived from ZIKV infected and vaccinated individuals is a critical component for characterizing immune response to infection and vaccine efficacy. This protocol describes a modified plaque reduction neutralization 50 (PRNT50) assay that includes an immunostaining step to improve reproducibility and throughput of the assay.
Zika virus (ZIKV) is a newly emerged mosquito-borne flavivirus that has been associated with birth defects of babies born to ZIKV-infected mothers. Neutralization activity of serum derived from ZIKV infected and vaccinated individuals is a critical component for characterizing immune response to infection and vaccine efficacy. This protocol describes a modified plaque reduction neutralization 50 (PRNT50) assay that includes an immunostaining step to improve reproducibility and throughput of the assay.
